Focus Stocks
Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results Teleconference and Webcast
Published on Thursday, 09 February 2012 16:13 Written by TradersHuddle Staff
SAN FRANCISCO, Feb. 9, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss fourth quarter and full year 2011 financial results, as well as provide a general business overview, on Wednesday, February 22, 2012, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the fourth quarter and full year ended December 31, 2011 will be released after market closes on February 22, 2012.
Interested parties may access a live webcast of the teleconference on the company's website at:
http://www.onyx-pharm.com/investors/event-calendar
or by dialing 847-585-4405 and using the passcode 31754065#. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 31754065# approximately one hour after the teleconference concludes. The replay will be available through March 7, 2012.
About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.
SOURCE Onyx Pharmaceuticals, Inc.
Related Articles
- New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer Submitted by Bayer
- Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
- Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of Clinical Oncology Annual Meeting
- Onyx Pharmaceuticals Reports First Quarter 2012 Financial Results
- Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
- Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
- Onyx Pharmaceuticals to Report First Quarter 2012 Financial Results After Market on May 2, 2012
- Phase 3 Trial of Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival
- Onyx Pharmaceuticals Announces Cell Publication Demonstrating Selectivity of Immunoproteasome Inhibitor ONX 0914
- Onyx Pharmaceuticals Completes Enrollment in ASPIRE Phase 3 Carfilzomib Combination Trial for the Potential Treatment of Relapsed Multiple Myeloma
Related Partner Headlines
- New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer Submitted by Bayer - Benzinga
- From Earlier: Phase 3 MISSION trial of Nexavar in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival - Benzinga
- Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma - Benzinga
- Onyx Stock Hits New 52-Week High (ONXX) - TheStreet.com
- Notable Options Activity in Onyx Pharmaceuticals, Inc - Benzinga
- Onyx Pharmaceuticals Completes Enrollment in ASPIRE Phase 3 Carfilzomib Combination Trial for the Potential Treatment of Relapsed Multiple Myeloma - Benzinga
- Notable Call Options Activity in Onyx Pharmaceuticals - Benzinga
- Morgan Stanley Initiates Coverage on Onyx Pharmaceuticals at Underweight, Announces PT of $38 - Benzinga
- Onyx Pharmaceuticals to Consider Sale: Reports - TheStreet.com
- Onyx Rises On Unusually High Volume (ONXX) - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Top 4 Small-Cap Stocks In The Health Care Plans Industry With The Highest Revenue - Benzinga -
Top 4 Small-Cap Stocks In The Heavy Construction Industry With The Lowest PEG Ratio - Benzinga -
Earnings Scheduled For May 25 - Benzinga -
Cramer's 'Mad Money' Recap: Big Government Not Protecting the Little Guys - TheStreet.com -
The Global Retrenchment Accelerates - TheStreet.com -
Bain Capital Sent 0,000-Plus to Obama and Dems in 2008 - TheStreet.com -
Market Preview: Low-Grade Uncertainty - TheStreet.com -
The EPA's Dangerous Game - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Syngenta settles atrazine litigation in the USA -
Atrazine Litigation Settled -
eMazzanti Attains Xerox Gold Partner Status -
USFS, BLM Hire Youth for Public Lands Conservation Jobs -
SCVBank Elects Scott K. Rushing as New Chairman -
Heritage Oaks Bancorp to Pay Trust Preferred Interest and Accumulated TARP Dividends -
Law Office of Brodsky & Smith, LLC Announces Investigation of Ariba, Inc. -
Following Its Record 73% Jump FY 2011 Revenue, Privately-Held Milton Security Group Reports Repeat Double-Digit Sales Growth for First Quarter 2012









